









Markets
/
Stocks
/
nasdaq-inva
/

Innoviva Inc

INVA

22.660USD

0.0000.00%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

1.96BMarket Cap

5.63P/E TTM



Innoviva Inc

22.660

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Innoviva Inc

Currency: USD Updated: 2026-03-27

Key Insights

Innoviva Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 2 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.20.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Innoviva Inc's Score

Industry at a Glance

Industry Ranking

2 / 157

Overall Ranking

15 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Innoviva Inc Highlights

StrengthsRisks

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 32.49% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 411.33M.

Fairly Valued

The company’s latest PE is 5.63, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 80.86M shares, decreasing 2.32% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 129.52K shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

33.200

Target Price

+51.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Innoviva Inc is 9.08, ranking 13 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 114.61M, representing a year-over-year increase of 24.84%, while its net profit experienced a year-over-year increase of 707.36%.

Score

Industry at a Glance

Previous score

9.08

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.82

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Innoviva Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Innoviva Inc is 7.66, ranking 52 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 5.63, which is 803.70% below the recent high of 50.90 and 508.26% above the recent low of -22.99.

Score

Industry at a Glance

Previous score

7.66

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 2/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Innoviva Inc is 8.00, ranking 57 out of 157 in the Pharmaceuticals industry. The average price target is 33.00, with a high of 45.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

33.200

Target Price

+51.46%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Innoviva Inc

INVA

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Innoviva Inc is 8.83, ranking 9 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 23.35 and the support level at 21.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.34

Change

1.49

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.020

Buy

RSI(14)

57.039

Neutral

STOCH(KDJ)(9,3,3)

69.276

Buy

ATR(14)

0.512

Low Volatility

CCI(14)

161.562

Buy

Williams %R

33.013

Buy

TRIX(12,20)

-0.057

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

22.348

Buy

MA10

22.163

Buy

MA20

22.243

Buy

MA50

21.821

Buy

MA100

21.138

Buy

MA200

20.189

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Innoviva Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 108.15%, representing a quarter-over-quarter increase of 6.92%. The largest institutional shareholder is The Vanguard, holding a total of 7.90M shares, representing 10.67% of shares outstanding, with 6.62% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

8.34M

+3.04%

The Vanguard Group, Inc.

Star Investors

7.08M

-1.09%

Dimensional Fund Advisors, L.P.

4.33M

+0.84%

Renaissance Technologies LLC

Star Investors

4.59M

-3.65%

Sarissa Capital Management, L.P.

2.82M

State Street Investment Management (US)

2.56M

+4.05%

Arrowstreet Capital, Limited Partnership

2.36M

+38.05%

American Century Investment Management, Inc.

2.35M

+13.75%

Bank of Nova Scotia

Star Investors

2.18M

-39.23%

Systematic Financial Management, L.P.

2.12M

+2.78%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Innoviva Inc is 7.78, ranking 35 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.